Cabaletta Bio appoints general counsel

Philadelphia-based Cabaletta Bio has hired Michael Gerard as general counsel.

Gerard was most recently associate general counsel at Spark Therapeutics, a member of the Roche Group. During his time with Spark, he supported the global gene therapy manufacturing, business development, technical development, supply chain, quality, alliance management, real estate, IT and facilities teams.

Before working at Spark, Gerard held roles of increasing responsibility at Sandoz, a division of the Novartis Group, including executive director and associate general counsel for business development and licensing, strategy and portfolio. He has also worked as assistant general counsel at Aramark.

Gerard began his legal career in private practice at K&L Gates and later Morrison & Foerster before moving in-house.

Nasdaq-listed Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies.

Steven Nichtberger, CEO and co-founder of Cabaletta Bio, says in a statement: ‘We are very pleased to welcome Mike to the executive team… In addition to his dynamic and highly relevant legal experience, Mike shares our vision, our values and our passion for the pursuit of cures for patients with autoimmune diseases.’